

B. AMENDMENTS TO THE CLAIMS

1. (Twice Amended). A pharmaceutical comprising:

(a) a therapeutic antibody that binds to a therapeutic target, said antibody being modified with a peptide that reduces binding of the antibody to the therapeutic target, said modified antibody being effective for reducing side effects caused by an immune response against the antibody and for producing a therapeutic effect by binding to the therapeutic target, wherein said antibody includes an antibody combining site that binds to the therapeutic target, and said peptide is bound to the antibody combining site of said antibody; and (b) a pharmaceutical carrier.

2-5 Cancelled.

6. (Previously Presented). The pharmaceutical of Claim 1 wherein the avidity of the modified antibody combined with the peptide is at least 4-fold less than the avidity of the unmodified antibody and no more than 100-fold less.

7. (Original). The pharmaceutical of Claim 6 wherein the antibody is an aglycosylated antibody.

8. (Original). The pharmaceutical of Claim 7 wherein only one of the chains of the antibody has a peptide linked thereto that binds to the antibody combining site.

9. (Previously Presented). The pharmaceutical of Claim 1 wherein the peptide is reversibly bound to the antibody combining site, whereby the amount of antibody that binds to the target increases as the peptide is displaced from the antibody binding site.

10. (Previously Presented). The pharmaceutical of Claim 9 wherein the peptide bound to the antibody combining site is also linked to the antibody.

11. Cancelled.
12. (Previously Presented). The pharmaceutical of Claim 10 wherein the Fc portion of the antibody is aglycosylated.
13. (Previously Presented). The pharmaceutical of Claim 10 wherein binding of the antibody to the Fc receptor is essentially eliminated.
14. (Original). The pharmaceutical of Claim 10 wherein the antibody is a non-human antibody.
15. (Original). The pharmaceutical of Claim 10 wherein the antibody is a chimeric antibody.
16. (Withdrawn). A process for treating a mammal, comprising administering to a mammal the pharmaceutical of Claim 1 in an amount effective to both treat the mammal and reduce side effects against the protein.
17. (Previously Presented). The pharmaceutical of Claim 10 wherein the antibody is a humanized antibody.